Loading...
China Shineway Pharmaceutical Group Limited
CSWYF•PNK
Healthcare
Drug Manufacturers - Specialty & Generic
$1.004
$0.00(0.00%)
China Shineway Pharmaceutical Group Limited (CSWYF) Financial Performance & Income Statement Overview
Review China Shineway Pharmaceutical Group Limited’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
-16.35%
↓ 16.35%
Operating Income Growth
-13.63%
↓ 13.63%
Net Income Growth
-13.35%
↓ 13.35%
Operating Cash Flow Growth
3.27%
↑ 3.27%
Operating Margin
20.68%
↑ 20.68%
Gross Margin
75.00%
↑ 75.00%
Net Profit Margin
22.33%
↑ 22.33%
ROE
6.96%
↑ 6.96%
ROIC
2.23%
↑ 2.23%
China Shineway Pharmaceutical Group Limited (CSWYF) Income Statement & Financial Overview
Review China Shineway Pharmaceutical Group Limited's (CSWYF) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q2 2024 | Q4 2023 | Q3 2023 |
|---|---|---|---|---|
| Revenue | $1.69B | $2.09B | $292.93M | $145.04M |
| Cost of Revenue | $431.78M | $514.51M | $72.99M | $36.14M |
| Gross Profit | $1.26B | $1.57B | $219.94M | $108.90M |
| Gross Profit Ratio | $0.74 | $0.75 | $0.75 | $0.75 |
| R&D Expenses | $55.78M | $44.75M | $8.61M | $4.26M |
| SG&A Expenses | $928.37M | $966.87M | $158.21M | $78.33M |
| Operating Expenses | $984.15M | $1.01B | $166.82M | $73.11M |
| Total Costs & Expenses | $1.42B | $1.53B | $239.81M | $109.25M |
| Interest Income | $0.00 | $0.00 | $5.91M | $3.17M |
| Interest Expense | $0.00 | $0.00 | $354917.00 | $0.00 |
| Depreciation & Amortization | $85.21M | $80.68M | $12.59M | $5.46M |
| EBITDA | $360.63M | $641.25M | $91.64M | $31.77M |
| EBITDA Ratio | $0.21 | $0.31 | $0.22 | $0.22 |
| Operating Income | $275.42M | $560.57M | $53.13M | $26.30M |
| Operating Income Ratio | $0.16 | $0.27 | $0.18 | $0.18 |
| Other Income/Expenses (Net) | $8.22M | $301.51M | $25.57M | $12.66M |
| Income Before Tax | $283.64M | $862.08M | $78.70M | $38.96M |
| Income Before Tax Ratio | $0.17 | $0.41 | $0.27 | $0.27 |
| Income Tax Expense | $70.06M | $235.60M | $12.58M | $6.23M |
| Net Income | $213.57M | $626.48M | $66.12M | $32.74M |
| Net Income Ratio | $0.13 | $0.30 | $0.23 | $0.23 |
| EPS | $0.28 | $0.83 | $0.09 | $0.04 |
| Diluted EPS | $0.28 | $0.83 | $0.09 | $0.04 |
| Weighted Avg Shares Outstanding | $762.76M | $755.40M | $755.40M | $758.80M |
| Weighted Avg Shares Outstanding (Diluted) | $755.40M | $755.40M | $755.40M | $755.40M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan